

CLINICAL RESEARCH IN INFECTIOUS DISEASES

SAFETY SUMMARY REPORT

Prepared for the Safety Monitoring Committee

for

DMID Protocol 20-0003:

**Phase I, Open-Label, Dose-Ranging Study of the Safety and
Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy
Adults**

APPENDICES

02 JUNE 2020

Prepared and distributed by:
Statistical and Data Coordinating Center (SDCC)
Emmes
Rockville, Maryland

THIS COMMUNICATION IS PRIVILEGED AND CONFIDENTIAL

TABLE OF CONTENTS

APPENDIX A: Adverse Event Definitions	2
APPENDIX B: Listing of Non-Serious, Unsolicited, Moderate or Mild, or Severe Adverse Events	5
APPENDIX C1: Solicited Systemic Events.....	34
APPENDIX C2: Solicited Local Events	220
APPENDIX D: Attribution for Systemic Solicited Events that Contribute to Halting Criteria.....	355
APPENDIX E: Listing of Abnormal Clinical Laboratory Results.....	356
APPENDIX F: Vital Signs Listing	726
APPENDIX G1: Listing of Protocol Deviations.....	763
APPENDIX G2: Listing of Non-Subject Deviations	769
APPENDIX H: Listing of Pregnancies	770

APPENDIX A: Adverse Event Definitions

(Excerpted from Protocol version 3.0, 30 March 2020)

Definition of Adverse Event (AE)

AEs means any untoward medical occurrence associated with the use of an intervention in humans, whether or not considered intervention-related (21 CFR 312.32 (a)). An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of medicinal (investigational) product.

Any medical condition that is present at the time that the subject is screened will be considered as baseline and not reported as an AE. However, if the severity of any pre-existing medical condition increases, it should be recorded as an AE.

AEs can be further divided into solicited AEs and unsolicited AEs. Solicited AEs are those for which the study team will specifically query the subject whether they occurred. Unsolicited AEs are those events that the subject report occurring without being queried about the specific event.

All AEs will be assessed for severity and relationship to study intervention (see section 8.3.3 of the protocol). Reporting of all AEs, solicited and unsolicited, will occur during the period from study product administration at Day 1 through 28 days after the last vaccination. After Day 57 through the end of study on Day 394, only SAEs, MAAEs, and NOCMCs will be recorded as AEs.

All AEs, solicited and unsolicited, will be captured on the appropriate DCF. Information to be collected for AEs includes event description, date of onset, assessment of severity, relationship to study product and alternate etiology (assessed only by those with the training and authority to make a diagnosis and listed on the Form FDA 1572 as the participating site PI or appropriate sub-investigator), date of resolution, seriousness, and outcome. AEs occurring during the study-collection and reporting period will be documented appropriately regardless of relationship.

AEs will be followed to resolution or stabilization.

Severity of Adverse Events: All AEs or SAEs will be assessed for severity, according to the toxicity grading scales in the FDA “Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials”.

For AEs not included in the protocol-defined grading system, the following guidelines will be used to describe severity.

- **Mild (Grade 1):** Events that are usually transient and may require only minimal or no treatment or therapeutic intervention and generally do not interfere with the subject’s usual activities of daily living.
- **Moderate (Grade 2):** Events that are usually alleviated with additional specific therapeutic intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the research subject.

Appendix A (continued) **Adverse Events Definitions**

(Excerpted from Protocol version 3.0, 30 March 2020)

- **Severe (Grade 3):** Events interrupt usual activities of daily living, or significantly affects clinical status, or may require intensive therapeutic intervention. Severe events are usually incapacitating.

AEs characterized as intermittent require documentation of onset and duration of each episode. The start and stop date of each reported AE will be recorded on the appropriate DCF. Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of intensity.

Relationship to Study Intervention: For each reported adverse reaction, the participating site PI or qualified designee must assess the relationship of the event to the study product using the following guidelines:

- **Related** – The AE is known to occur with the study intervention, there is a reasonable possibility that the study intervention caused the AE, or there is a temporal relationship between the study intervention and event. Reasonable possibility means that there is evidence to suggest a causal relationship between the study intervention and the AE.
- **Not Related** – There is not a reasonable possibility that the administration of the study intervention caused the event, there is no temporal relationship between the study intervention and event onset, or an alternate etiology has been established.

Definition of Serious Adverse Event (SAE)

An SAE is defined in 21 CFR 312.32 as follows: “An AE or suspected adverse reaction is considered serious if, in the view of either the participating site PI or appropriate sub-investigator or the sponsor, it results in any of the following outcomes:

- Death,
- a life-threatening AE,
- inpatient hospitalization or prolongation of existing hospitalization,
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions,
- or a congenital anomaly/birth defect.

Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in inpatient hospitalization, or the development of drug dependency or drug abuse.

Appendix A (continued)
Adverse Events Definitions

(Excerpted from Protocol version 3.0, 30 March 2020)

“Life-threatening” refers to an AE that at occurrence represents an immediate risk of death to a subject. An event that may cause death if it occurs in a more severe form is not considered life-threatening. Similarly, a hospital admission for an elective procedure is not considered an SAE.

All SAEs, as with any AE, will be assessed for severity and relationship to study intervention.

All SAEs will be recorded on the appropriate SAE DCF.

All SAEs will be followed through resolution or stabilization by a study clinician, licensed to make medical diagnoses and listed on the Form FDA 1572 as the participating site PI or appropriate sub-investigator.

All SAEs will be reviewed and evaluated by DMID and will be sent to the SMC (for periodic review unless related) and IRB/IEC.

**APPENDIX B:
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events**

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID:						(b) (6) AE Number: 001			
Petechiae R Elbow	14 (8)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Petechiae
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID:						(b) (6) AE Number: 001			
Vomiting	0 (0)	Mild	Not related	Other: brushing tongue	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID:						(b) (6) AE Number: 002			
Shortness of Breath With Strenuous Activity	25 (17)	Mild	Not related	Other: Deconditioning	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Dyspnoea exertional
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID:						(b) (6) AE Number: 001			
Abdominal Gas	4 (0)	Mild	Not related	Other medical condition or illness: food intolerance	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Flatulence

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Systolic Hypertension	28 (8)	Mild	Not related	Other: Recent exertion	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Erythema	14 (14)	Mild	Not related	Study procedure: reaction to tape adhesive	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Erythema
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Sore Throat	1 (3)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Sore Throat	15 (2)	Mild	Not related	Other: environmental	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Blood Draw Site	8 (6)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Right Neck Strain	6 (2)	Mild	Not related	Other medical condition or illness: lifting weight	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Contact Dermatitis	3 (9)	Mild	Not related	Study procedure: tape adhesive reaction	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis contact
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Cut On Right Index Finger	2 (2)	Mild	Not related	Other: accidental trauma	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin laceration

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Vomiting	1 (0)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Hives On Lower Extremities	5 (1)	Mild	Related	N/A	WD- Drug withdrawn	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Urticaria
Comments: Has had episodes about once per year of hives in past, sometimes due to cat allergy and other times without known etiology. Denies noting relationship to particular activity but occurs when outdoors.									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Arm Weakness	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscular weakness
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Bruise at Blood Draw Site	0 (8)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 003									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Bruise at Blood Draw Site	8 (3)	Mild	Not related	Study procedure: venipuncture trauma	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Left Palm Abrasion	5 (7)	Mild	Not related	Other: Trauma	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 001									
Vomiting	22 (1)	Moderate	Not related	Other medical condition or illness: Sinus Headache	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Fatigue	20 (3)	Mild	Not related	Other medical condition or illness: Seasonal Allergies	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Fatigue
Comments: Had mild fatigue (in retrospect) for 2 days prior to onset of sinus headache. Seasonal allergies are asymptomatic now.									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Skin Irritation Encircling Injection Site	1 (8)	Mild	Not related	Study procedure: skin irritation from band aid	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site irritation
Comments: Reddened, puffy skin the size and shape of the dot bandaid place over the injection site. No reaction in the center of the circle.									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 004									
Bruises	14 (Ongoing)	Mild	Not Related	Other - trauma from heavy weight	Not Applicable	No		Injury, poisoning and procedural complications	Contusion
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 005									
Presyncope	18 (0)	Mild	Not related	Other: Sudden postural change	Not applicable	No	Recovered /resolved	Nervous system disorders	Presyncope
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 004									
Bruise at Blood Draw Site	8 (7)	Mild	Not related	Study procedure: Venipuncture trauma	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 005									
Muscle Strain	11 (3)	Mild	Not related	Other: heavy lifting	Not applicable	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 006									
Bruise On Right Shoulder	25 (Ongoing)	Mild	Not related	Other: trauma from carrying load	Not applicable	No		Injury, poisoning and procedural complications	Contusion
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Elevated Heart Rate	13 (14)	Mild	Not related	Other: Caffeine ingestion	Dose not changed	No	Recovered /resolved	Investigations	Heart rate increased
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Sore Throat	4 (3)	Mild	Not related	Other medical condition or illness: Seasonal Allergies	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Lower Back Muscle Strain	9 (6)	Moderate	Not related	Other: Exercise	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Muscle strain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise On Arm at Injection Site	6 (6)	Mild	Not related	Study procedure: Related to injection	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Burn On Wrist	14 (27)	Mild	Not related	Other: oven burn	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Thermal burn
Comments: 20 mm burn on left wrist from cooking									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Dizziness	1 (1)	Mild	Not related	Study procedure: phlebotomy and dehydration	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Injection Site	1 (13)	Mild	Not related	Study procedure: trauma from needle	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Vasodilation On Bilateral Hands	3 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Vascular disorders	Vasodilatation
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Injection Site Itching	2 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Injection Site	0 (15)	Mild	Not related	Study procedure: Vaccine injection	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Decreased Appetite	0 (7)	Mild	Related	N/A	Dose not changed	No	Recovered/resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 003									
Itching at Injection Site	7 (1)	Mild	Related	N/A	Dose not changed	No	Recovered/resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Nasal Congestion	1 (0)	Mild	Not related	Other medical condition or illness: seasonal allergies	Dose not changed	No	Recovered/resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
R Breast Pain	20 (4)	Mild	Not related	Other: Premenstrual	Dose not changed	No	Recovered/resolved	Reproductive system and breast disorders	Breast pain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Bradycardia	14 (Ongoing)	Mild	Not related	Other: Conditional athlete	Not applicable	No	Recovering /resolving	Cardiac disorders	Bradycardia
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 001									
Abdominal Cramping	0 (1)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Neck Pain	2 (1)	Mild	Not related	Other: Positional stress	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Neck pain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Back Muscle Strain	22 (Ongoing)	Mild	Not related	Other: positional	Not applicable	No		Injury, poisoning and procedural complications	Muscle strain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Diaphragmatic Cramping	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Diaphragmatic spasm
Comments:									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 004									
Decreased Appetite	0 (3)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 005									
Feeling of Restlessness	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Feeling jittery
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 006									
Eye Irritation	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Eye disorders	Eye irritation
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 007									
Stomach Upset	4 (0)	Mild	Not related	Other: dietary intolerance	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal discomfort
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 008									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Itching at Injection Site	3 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 009									
Dark Stools	4 (11)	Mild	Not related	Other: Dietary change	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Faeces discoloured
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Headache	10 (0)	Moderate	Not related	Other medical condition or illness: has a baseline history of Headache	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Headache	27 (0)	Moderate	Not related	Other medical condition or illness: Tension Headaches	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Decreased Appetite	0 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Worsening Vaginal Itching	6 (Ongoing)	Mild	Not related	Other medical condition or illness: Vaginal Itching	Dose not changed	No	Recovering /resolving	Reproductive system and breast disorders	Vulvovaginal pruritus
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 003									
Headache	8 (12)	Mild	Not related	Other: stress	Dose not changed	No	Recovered /resolved	Nervous system disorders	Headache
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 004									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Lip Bumps	21 (7)	Mild	Not related	Other medical condition or illness: dermatitis	Dose not changed	No	Recovered /resolved	Gastrointestinal disorders	Lip disorder
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Redness at Vaccine Site	12 (3)	Moderate	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments: Subject seen today for routine follow up visit. First noted it on 27APR2020. Size was 92mm.									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Hypertension	6 (0)	Mild	Not related	Study procedure: Failed to repeat blood pressure measurement	Dose not changed	No	Recovered /resolved	Vascular disorders	Hypertension
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Right Knee Pain	2 (0)	Mild	Not related	Other: inactivity	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Arthralgia

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Sore Throat	24 (3)	Mild	Not related	Other medical condition or illness: Viral illness	WD- Drug withdrawn	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Injection Site Redness	10 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site erythema
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Vaginal Spotting	0 (1)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Reproductive system and breast disorders	Vaginal haemorrhage
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Itching at Injection Site	7 (4)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site pruritus

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Bradycardia	14 (14)	Mild	Not related	Other: physical conditionin g	Dose not changed	No	Recovered /resolved	Cardiac disorders	Bradycardia
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 005									
Hypotension Systolic	28 (Ongoing)	Mild	Not related	Other: Decreased activity level	Dose not changed	No		Vascular disorders	Hypotension
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Muscle Strain In Neck	11 (7)	Moderate	Not related	Other: sleeping position	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle strain
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Hypoglycemia	7 (Ongoing)	Moderate	Not related	Other: decreased PO intake	Not applicable	No	Recovering /resolving	Metabolism and nutrition disorders	Hypoglycaemia
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 001									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Stomachache	7 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Abdominal pain upper
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Muscle Spasms	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Muscle spasms
Comments: in neck and back, spasms cycled over minutes between clench and release.									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Loss of Appetite	1 (0)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Vomiting	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Gastrointestinal disorders	Vomiting
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Lightheadedness	1 (0)	Severe	Related	N/A	Not applicable	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 004									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA® System Organ Class	MedDRA® Preferred Term
Syncope	1 (0)	Severe	Related	N/A	Not applicable	No	Recovered /resolved	Nervous system disorders	Syncope
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 005									
Bruise at Phlebotomy Site R Arm	1 (Ongoing)	Mild	Not related	Other: trauma from blood draw	Not applicable	No		General disorders and administration site conditions	Vessel puncture site bruise
Comments: This was from blood draw at urgent care visit, not a study visit, per query.									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 006									
Recurrence of Scintillating Scotomata	13 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Eye disorders	Scintillating scotoma
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 002									
Loss of Appetite	0 (2)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Metabolism and nutrition disorders	Decreased appetite
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6) AE Number: 003									
Sweating	0 (1)	Moderate	Related	N/A	Not applicable	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Hyperhidrosis
Comments:									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 004									
Insomnia	7 (Ongoing)	Mild	Not related	Other: situational stress	Not applicable	No		Psychiatric disorders	Insomnia
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 005									
Anxiety	1 (Ongoing)	Mild	Related	N/A	Not applicable	No		Psychiatric disorders	Anxiety
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 003									
Malaise	1 (1)	Moderate	Related	N/A	Not applicable	No	Recovered/resolved	General disorders and administration site conditions	Malaise
Comments:									
Vaccination Group: 250 mcg mRNA-1273 (18-55 years), Dose #: 02, Subject ID: (b) (6), AE Number: 004									
Night Sweats	2 (0)	Moderate	Related	N/A	Not applicable	No	Recovered/resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6), AE Number: 001									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Headache	27 (0)	Mild	Not related	Other medical condition or illness: tension headaches	Dose not changed	No	Recovered/resolved	Nervous system disorders	Headache
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Worsening of Sciatica	5 (1)	Mild	Not related	Other: Exercise paddle boating	Dose not changed	No	Recovered/resolved	Nervous system disorders	Sciatica
Comments: Subject has pre-existing sciatica pain that occurs occasionally. Subject mentioned worsening of sciatica following paddle boating.									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Exposure to Inhaled Irritants	12 (0)	Moderate	Not related	Other: exposure to onions	Dose not changed	No	Recovered/resolved	Injury, poisoning and procedural complications	Exposure via inhalation
Comments: Subject went onion picking and developed tearing and rhinorrhea. She took Benadryl with resolution of her symptoms.									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Sore Throat	1 (1)	Mild	Not related	Other medical condition or illness: SEASONAL ALLERGIES	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments: She has seasonal allergies at part of her past medical history. Her sore throat felt similar to prior seasonal allergy issues that she has had due to high pollen count.									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Injection Site	1 (11)	Mild	Not related	Study procedure: Vaccine Administration	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Vaccination Site	0 (4)	Mild	Not related	Study procedure: vaccination procedure	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vaccination site bruising
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Diastolic Hypertension	28 (Ongoing)	Mild	Not related	Other: labile blood pressure	Dose not changed	No	Recovering/resolving	Vascular disorders	Diastolic hypertension
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: (b) (6) AE Number: 001									
No Appetite	1 (1)	Moderate	Related	N/A	Not Applicable	No	Recovered/Resolved	Metabolism and nutrition disorders	Decreased appetite
Comments: Combined solicited systemic Symptoms kept subject from eating for > 24 hours.									
Vaccination Group: 25 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: (b) (6) AE Number: 001									
Insomnia	0 (1)	Mild	Related	N/A	Not applicable	No	Recovered/resolved	Psychiatric disorders	Insomnia
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Nasal Congestion	13 (2)	Moderate	Not related	Other medical condition or illness: seasonal allergies	Dose not changed	No	Recovered/resolved	Respiratory, thoracic and mediastinal disorders	Nasal congestion
Comments: took pseudoephedrine once, currently mild with improved minimal residual symptoms									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Sore Throat	21 (1)	Mild	Not related	Other: Environmental Exposure	Dose not changed	No	Recovered /resolved	Respiratory, thoracic and mediastinal disorders	Oropharyngeal pain
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Paronychia	2 (13)	Moderate	Not related	Other medical condition or illness: Bacterial Infection	Dose not changed	No	Recovered /resolved	Infections and infestations	Paronychia
Comments: Redness & Swelling that developed 25APR2020. This worsened on 26APR2020 and she presented to Urgent Care where she had an incision and drainage performed under local anesthetics (Lidocaine). She was given a dose of Ceftriaxone and discharged on Sulfamethoxazole-Trimethoprim.									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Maculopapular Rash	9 (Ongoing)	Moderate	Not related	Other drug: Sulfamethoxazole-Trimethoprim	WD- Drug withdrawn	No	Recovering /resolving	Skin and subcutaneous tissue disorders	Rash maculo-papular
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Systolic Hypertension	14 (15)	Mild	Not related	Other: labile blood pressure	Dose not changed	No	Recovered /resolved	Vascular disorders	Systolic hypertension

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Hypoglycemia	8 (5)	Severe	Not related	Other: fasting and vigorous exercise	Dose not changed	No	Recovered /resolved	Metabolism and nutrition disorders	Hypoglycaemia
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (56-70 years), Dose #: 02, Subject ID: (b) (6) AE Number: 001									
Vertigo	1 (0)	Mild	Related	N/A	Not applicable	No	Recovered /resolved	Ear and labyrinth disorders	Vertigo
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Sunburn	4 (9)	Mild	Not related	Other: Excessive sun exposure	Dose not changed	No	Recovered /resolved	Injury, poisoning and procedural complications	Sunburn
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bilateral Ankle Swelling	2 (1)	Mild	Not related	Other: Wore a constrictive pair of new socks	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Joint swelling
Comments:									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Lightheadedness	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Nervous system disorders	Dizziness
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Night Swcats	2 (2)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Night sweats
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 003									
Anxiety	4 (0)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	Psychiatric disorders	Anxiety
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Increased Energy	0 (3)	Mild	Related	N/A	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Energy increased
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
L Upper torso Musculoskeletal Pain	1 (12)	Moderate	Not related	Other: Bicycle accident	Dose not changed	No	Recovered /resolved	Musculoskeletal and connective tissue disorders	Musculoskeletal chest pain
Comments:									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Abrasion to L Elbow	1 (Ongoing)	Mild	Not related	Other: Bicycle accident	Dose not changed	No		Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Itching Lateral R Clavicle	0 (0)	Mild	Related	N/A	Dose not changed	No	Recovered/resolved	Skin and subcutaneous tissue disorders	Pruritus
Comments: 5-10 minute duration									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
L Upper Arm Abrasion	0 (10)	Mild	Not related	Other: Scratched arm while doing yardwork	Dose not changed	No	Recovered/resolved	Injury, poisoning and procedural complications	Skin abrasion
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Bruise at Injection Site	2 (10)	Mild	Not related	Study procedure: Needle trauma	Dose not changed	No	Recovered/resolved	General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 25 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 003									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] Sytem Organ Class	MedDRA [®] Preferred Term
Tick Bite	3 (Ongoing)	Mild	Not related	Other: Insect bite	Dose not changed	No		Injury, poisoning and procedural complications	Arthropod bite
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Dermatitis	0 (10)	Mild	Not related	Other: Reaction to adhesive on tape	Dose not changed	No	Recovered /resolved	Skin and subcutaneous tissue disorders	Dermatitis
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Injection Site	0 (Ongoing)	Mild	Not related	Study procedure: Needle trauma from vaccine	Dose not changed	No		General disorders and administration site conditions	Injection site bruising
Comments:									
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 002									
Bruise at Blood Draw Site	0 (Ongoing)	Mild	Not related	Study procedure: Needle trauma from phlebotomy	Dose not changed	No		General disorders and administration site conditions	Vessel puncture site bruise
Comments:									

Appendix B (continued)
Listing of Non-Serious, Unsolicited, Mild or Moderate, or Severe Adverse Events

Adverse Event	No. of Days Post Associated Vaccination (Duration)	Severity	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to AE	Outcome	MedDRA [®] System Organ Class	MedDRA [®] Preferred Term
Vaccination Group: 100 mcg mRNA-1273 (≥71 years), Dose #: 01, Subject ID: (b) (6) AE Number: 001									
Bruise at Blood Draw Site	3 (1)	Mild	Not related	Study procedure: Needle trauma from phlebotomy	Dose not changed	No	Recovered /resolved	General disorders and administration site conditions	Vessel puncture site bruise
Comments:									

**APPENDIX C1:
Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.4	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None

Report Date: 02JUN2020
Data Cutoff Date: 25MAY2020

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.4	None	None	None	None	None	Moderate
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	None	Moderate	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)
Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.5	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Mild	Moderate	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

**Appendix C1 (continued)
Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.1 (Mild)	Moderate	Moderate	Moderate	None	Moderate	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.5	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.6	None	Mild	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.6	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	None	Moderate	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	Moderate	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	None	None	None	Mild	Moderate	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.5	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	None	Moderate	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	Mild	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	Mild	Mild	Mild	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	Mild	None	Mild	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	Mild	None	Mild	Moderate	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.4	None	None	None	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 9	MA	N/A				Mild		
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.3	None	None	Mild	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.7	Mild	Moderate	Moderate	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	Mild	Mild	Mild	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.5	None	Moderate	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.5	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None

**Appendix C1 (continued)
 Solicited Systemic Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea	
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	Mild	None	None	None	None	
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.5	None	None	None	None	None	None	
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None	
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None	
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None	
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.3 (Mild)	Moderate	Moderate	Moderate	Moderate	Moderate	Mild	Moderate
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	Moderate	Moderate	Moderate	Mild	Mild	None	

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.1	None	None	Mild	None	Mild	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.8	Mild	Moderate	Moderate	Mild	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	Mild	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	39.2 (Severe)	Moderate	Moderate	Moderate	Moderate	Moderate	Mild
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	Moderate	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.9	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.3	None	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	37.3	Moderate	Mild	Moderate	Moderate	Moderate	Moderate
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.4	Moderate	Moderate	Moderate	Moderate	Moderate	Moderate
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.9	None	Mild	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	38.4 (Mild)	Mild	Mild	Mild	None	Mild	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.9	None	Moderate	Mild	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.9	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.4	None	Moderate	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)										

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	Moderate	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.8	Mild	Moderate	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	Mild	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.7	Moderate	Moderate	Moderate	Moderate	Mild	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	Mild	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	Mild	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 12	MA	N/A			Mild			
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	MA	36.7	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37	Mild	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	Mild	None	None	None	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	35.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	Moderate	None	None	None	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	Moderate	Moderate	Mild	Mild	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.9	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	Mild	None	Moderate	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	Mild	None	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.8	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	Mild	Mild	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.4	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.7	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	36.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	Mild	Mild	Mild	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.4	None	None	Mild	Mild	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	37.8	Moderate	Moderate	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	36.8	None	None	Mild	None	Mild	Mild
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.2	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	36.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	36.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	36.2	None	Mild	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	36.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	36.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	36.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	35.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	35.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	35.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	35.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.4	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.5	None	Moderate	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	Mild	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	Moderate	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Moderate	None	Mild	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	None	Mild	None	None	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37	None	Mild	Mild	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	Mild	Moderate	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.2	Mild	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	Mild	Mild	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.1	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Mild	Mild	None	None	Moderate	Mild
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37	None	None	None	None	Mild	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	Mild	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.1	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.4	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.2	None	Mild	None	None	Moderate	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	Mild	Mild	Mild	Moderate	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.5	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.4	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	Moderate	None	None	Mild	Moderate
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.3 (Mild)	Mild	None	Mild	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.6	None	Moderate	Moderate	Moderate	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.4 (Mild)	Moderate	None	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38 (Mild)	Mild	None	None	Mild	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.7	None	None	None	Mild	Mild	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	37.5	None	Mild	Mild	None	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.3	None	None	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.4	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.4	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.4	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	36.8	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.4	Mild	Mild	None	None	Moderate	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.8	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.8 (Moderate)	Severe	Severe	Moderate	Moderate	Moderate	Mild
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	36.8	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	37.5	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	37.2	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	37.2	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.6 (Moderate)	Severe	None	Severe	None	None	Severe
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	37.3	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	36.8	None	Mild	Mild	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	36.8	None	Mild	Mild	None	Moderate	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	36.7	None	Mild	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.6	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	N/A	Not Done	Not Done	Not Done	Not Done	Not Done	Not Done
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	37.3	Mild	Moderate	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	37.7	None	Mild	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	36.7	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	N/A	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	38.2 (Mild)	Moderate	Moderate	Mild	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	37.2	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	37.1	None	Mild	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	36.7	None	None	None	None	None	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	37.1	None	None	None	None	Mild	None
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	37.1	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.6	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	Mild	None